Analyst
Jefferies
Equibles does not estimate personal net worth.
Cha Cha Yang is recorded as Analyst at Jefferies. Cha Cha Yang has spoken on 6 earnings calls and 1 other investor event across 4 companies, most recently for Nektar Therapeutics on November 12, 2026. Those appearances were for Nektar Therapeutics (NKTR), SAB Biotherapeutics, Inc. (SABS), Tg Therapeutics, Inc. (TGTX) and Wave Life Sciences, Inc. (WVE). The companies whose calls Cha Cha Yang spoke on are classified in the Healthcare sector.
“I also have a question on the vitiligo selection program. If you could tell us more about how you are choosing patients and which patients you're choosing to prioritize, whether that's active disease patients or patients with stable disease, where the goal might be primarily repigmentation.”
“It's always very informative and very colorful. I was wondering if you could give us some comments on the pretrial that happened last week, any color that you can give on the outcomes of that, and then what impact you expect those outcomes to have on your upcoming September trial.”
“So one is, can you tell us more about what drove the acceleration of recruitment for your Phase 2? And then the second one, also on prize for Phase 3, can you just speak to more about the package or the data that convinced the FDA to allow you to start the Phase III study?”
“One is whether you can speak more to your plans for your DTC campaign expansion and what we can expect to see from that going forward. And then two is you talked about persistence being longer than you expected, whether you can talk more about what's driving that.”
Jefferies
Analyst
Transcript header (unverified)
NKTR
Biotechnology · Healthcare
